PRIMARY MAST CELL ACTIVATION SYNDROME

View at publisher Summarise with VIRAT
Authors: MEHMET KILIÇ
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Mast cell activation syndrome (MCAS) is a heterogeneous, rare disease. In this disease, inappropriate mediator release from mast cells (MC) leads to severe, recurrent, and episodic symptoms. Primary MCAS is thought to increase mast cell numbers by decreasing mast cell apoptosis, leading to clinical symptoms affecting multiple systems. Clonal proliferation in primary MCAS is not malignant. There-fore, rather than malignancy-related findings due to an increase in mast cell number, there is abnormal mast cell activation and mediator release in response to environmental triggers, resulting from a change in the mediator release threshold. Three main variants of MCAS have been identified based on etiolo-gy: primary MCAS (clonal/monoclonal), secondary MCAS (reactive), and idiopathic MCAS. Primary MCAS patients have increased mast cell numbers and a decreased threshold for mediator release in response to non-IgE and IgE-mediated triggers. A patient is considered to have primary MCAS if mast cell proliferation is due to c-KIT mutations (typically D816V+) and the increased mast cell number exhibits increased surface expression of CD2, CD25, or CD30. In primary MCAS, multiple symptoms can occur simultaneously across many systems and organs of the body. Patients with primary MCAS present to the hospital with symptoms related to the skin (flushing, urticaria, angioedema), systemic (chronic fatigue, lymph node inflammation), upper/lower respiratory tract (irritation of the eyes, nose, mouth and throat, cough, shortness of breath), neuropsychiatric (headache, cognitive dysfunction, con-fusion, anxiety, mood disorders), gastrointestinal (nausea, reflux, vomiting, abdominal pain, diarrhea/ constipation) and cardiovascular system (orthostatic intolerance, palpitations, hypotension). In addi-tion, primary MCAS cases have been reported to be accompanied by disorders such as irritable bowel syndrome and small intestinal bacterial overgrowth, Ehlers-Danlos syndrome, and postural orthostat-ic tachycardia syndrome. To make a definitive diagnosis in a patient being evaluated for suspected MCAS, all three MCAS criteria must be positive. These criteria include the presence of recurrent systemic symptoms in at least two organ systems simultaneously, associated with mediators secreted by MCs; objective laboratory evidence of mast cell activation; and improvement of symptoms with antimediator therapies. Treatment for patients with MCAS includes identifying and preventing trigger-ing factors, using drugs that block mast cell mediator release and/or the mediators they release, and, in severe cases, using drugs that reduce the number of MCs. Since primary MCAS is a lifelong condition, patients are advised to use prophylactic treatment throughout their lives. Additionally, patients should be prescribed an adrenaline auto-injector for use in case of an acute reaction. Keywords: Mast cell activation syndrome; Primary mast cell activation syndrome; Classification; Diagnosis; Treatment

Fields of Study & Subjects

Mast cells and histamine Gastrointestinal motility and disorders Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Turkiye Klinikleri eBooks
Pages
215–228
Publication date
1 January 2026
Language
EN
Document type
Book chapter